sur GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics: Financial Report and Outlook
GenSight Biologics has reported its net cash position at the end of 2024, highlighting sufficient working capital through February 2025 thanks to capital increases completed at the end of the year. However, the company will still need to secure financing to cover its commitments beyond that date.
The company's cash position stands at €2.5 million, down from September 2024. The respective capital increases in November and December, totalling €4.3 million, nevertheless make it possible to consider continuing the Compassionate Access (CA) programme.
At the same time, the ANSM review process of the LUMEVOQ® dossier is underway, following the submission of the company's responses. Preparations for the RECOVER phase III clinical trial are also progressing.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de GENSIGHT BIOLOGICS S.A.